Abstract
The recent shortage of the brand name drug Fungizone has necessitated a change to generic formulations of amphotericin B deoxycholate. Clinical trials cannot be conducted in a timely manner to provide data on the safety and efficacy of these formulations. We therefore compared generic amphotericin B and Fungizone for activity and safety in the treatment of experimental invasive pulmonary aspergillosis (IPA) in persistently neutropenic rabbits. Fungizone and generic amphotericin B are similar in efficacy, pharmacokinetics, and safety in the treatment of experimental IPA.
Original language | English (US) |
---|---|
Pages (from-to) | 1642-1645 |
Number of pages | 4 |
Journal | Antimicrobial agents and chemotherapy |
Volume | 49 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2005 |
Externally published | Yes |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases